|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1150 - 0.1375|
|52 Week Range||0.0520 - 0.2100|
|Beta (5Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
San Diego, CA, Feb. 05, 2020 -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) is pleased to release a recent interview with company President | CEO Sean Carrick, on.
SAN DIEGO, CA , Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nascent Biotech, Inc. (NBIO) founder Dr. Mark C. Glassy will be presenting on “Navigating the Unique Challenges Presented in Immune Oncology trials” in San Diego on February 12th. The meeting will be attended by influential leaders in the Pharmaceutical and Investment community.
San Diego, CA, Jan. 15, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO), an emerging biotech company, with IND Clearance and IRB approval to begin Clinical trials for Brain Cancer, is very pleased to announce that Marble Arch Research Inc., a leading independent equity research provider, has produced a new investment research report on the Company. The updated report provides an overview of recent events, new initiatives, and the Company’s valuation relative to its peer group. The sponsored research update also carries a rating and a price target and can be accessed and requested by email at email@example.com.
SAN DIEGO, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO), a biopharmaceutical company focusing on the development of monoclonal antibodies for the treatment of various types of cancers, announces an agreement with TRITON FUNDS LP. “Brain cancer is a severely underserved market affecting up to 25,000 new patients annually in the US alone. The metastatic patient population adds an additional 175,000 patients. We are excited to finally begin treating patients,” added Mr. Carrick.
San Diego, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO), today announced they have entered into a contractual agreement in Orange County, CA to conduct Phase I human clinical trials on Nascent antibody, Pritumumab, for the treatment of brain cancer. Pritumumab, a unique monoclonal antibody that appears to bind selectively to a number of epithelial cancers, had been previously studied in Japan with very promising results in the treatment of brain cancer.
San Diego, CA, June 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO) announced today that two of its Senior Officers have converted the Company’s liability to them to common stock. Nascent CFO Lowell Holden stated, “I believe the Company has continued to be undervalued and is now positioned to add significant value. The IND clearance by the FDA, along with the pending commencement of clinical trials, gives me confidence in its growth. Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an IND application before the FDA required for Clinical trials. Its products are not commercially available.
Today's featured company Nascent Biotech, Inc. (NBIO) is unique among all our previous offerings. Today's offering is complicated, at least by small cap standards and, well, perhaps typical of a company whose cancer technology has been created and developed since 1982, and which has now just received an incredibly critical permission to enter human trials for brain cancer. In 1982, Japan-based Hideaki Hagiwara, Ph. D was seeking a way to help treat his mother's cervical cancer and approached U.S.-based Dr. Mark Glassy, a professor at UCSD.
San Diego, CA, April 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (NBIO) has moved their corporate offices to San Diego, CA. Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials in brain cancer. Its products are not commercially available.